Studying Heart Failure Risk in Postmenopausal Women Using Heart Tissue
Studies heart tissue from surgery patients to explore heart failure risk after menopause.
Plain-language title generated from the registry record
Registry title: Purinergic Signaling and the Postmenopausal Heart
Key facts
- Where
- Boston, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 88 years old?
Source: NCT06015776, who can take part
Where in United States
- Beth Israel Deaconess Medical CenterBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beth Israel Deaconess Medical Center
- Trial code
- NCT06015776
- Record updated
- 20 March 2026
- Original description
There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.Read full original descriptionShow less
PGC-1, Purines and the Postmenopausal Heart
There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.
Inclusion: Patients undergoing cardiac surgery under cardiopulmonary bypass.
Exclusion: Emergency surgery; Redo surgery; Estrogen or hormone replacement therapy; Pre-existing heart block; History of chronic heart failure; History of major kidney disease; Refusal to participate; Preexisting atrial fibrillation.